How do you approach G-CSF use when offering neoadjuvant chemoRT for lower extremity soft-tissue sarcoma?

i.e. doxorubicin, ifosfamide + RT. Do you worry about decreased locoregional control or increased toxicities with the use of G-CSF in combination with radiation therapy? If you do administer G-CSF, what is the preferred timing of administration?

1 Answer

Mednet MemberInvited Expert

Medical Oncology · University of Texas MD Anderson Cancer Center

Answered on

We don't use concurrent chemo and XRT so it is not an issue for us. I suppose the detrimental effect of XRT on cycling progenitors would depend on the field that is being irradiated. Typical extremity STS may not pose a big risk, but pelvis would.

Join for free or sign in to see the full answer